303 related articles for article (PubMed ID: 23259649)
1. Re-directed T cells for the treatment of fibroblast activation protein (FAP)-positive malignant pleural mesothelioma (FAPME-1).
Petrausch U; Schuberth PC; Hagedorn C; Soltermann A; Tomaszek S; Stahel R; Weder W; Renner C
BMC Cancer; 2012 Dec; 12():615. PubMed ID: 23259649
[TBL] [Abstract][Full Text] [Related]
2. Treatment of malignant pleural mesothelioma by fibroblast activation protein-specific re-directed T cells.
Schuberth PC; Hagedorn C; Jensen SM; Gulati P; van den Broek M; Mischo A; Soltermann A; Jüngel A; Marroquin Belaunzaran O; Stahel R; Renner C; Petrausch U
J Transl Med; 2013 Aug; 11():187. PubMed ID: 23937772
[TBL] [Abstract][Full Text] [Related]
3. Aberrant Lck Signal via CD28 Costimulation Augments Antigen-Specific Functionality and Tumor Control by Redirected T Cells with PD-1 Blockade in Humanized Mice.
Gulati P; Rühl J; Kannan A; Pircher M; Schuberth P; Nytko KJ; Pruschy M; Sulser S; Haefner M; Jensen S; Soltermann A; Jungraithmayr W; Eisenring M; Winder T; Samaras P; Tabor A; Stenger R; Stupp R; Weder W; Renner C; Münz C; Petrausch U
Clin Cancer Res; 2018 Aug; 24(16):3981-3993. PubMed ID: 29748183
[No Abstract] [Full Text] [Related]
4. A phase I clinical trial of single-dose intrapleural IFN-beta gene transfer for malignant pleural mesothelioma and metastatic pleural effusions: high rate of antitumor immune responses.
Sterman DH; Recio A; Carroll RG; Gillespie CT; Haas A; Vachani A; Kapoor V; Sun J; Hodinka R; Brown JL; Corbley MJ; Parr M; Ho M; Pastan I; Machuzak M; Benedict W; Zhang XQ; Lord EM; Litzky LA; Heitjan DF; June CH; Kaiser LR; Vonderheide RH; Albelda SM; Kanther M
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4456-66. PubMed ID: 17671130
[TBL] [Abstract][Full Text] [Related]
5. Overexpression and potential targeting of the oncofoetal antigen 5T4 in malignant pleural mesothelioma.
Al-Taei S; Salimu J; Lester JF; Linnane S; Goonewardena M; Harrop R; Mason MD; Tabi Z
Lung Cancer; 2012 Aug; 77(2):312-8. PubMed ID: 22498111
[TBL] [Abstract][Full Text] [Related]
6. Intracavitary 'T4 immunotherapy' of malignant mesothelioma using pan-ErbB re-targeted CAR T-cells.
Klampatsa A; Achkova DY; Davies DM; Parente-Pereira AC; Woodman N; Rosekilly J; Osborne G; Thayaparan T; Bille A; Sheaf M; Spicer JF; King J; Maher J
Cancer Lett; 2017 May; 393():52-59. PubMed ID: 28223167
[TBL] [Abstract][Full Text] [Related]
7. Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity.
Adusumilli PS; Cherkassky L; Villena-Vargas J; Colovos C; Servais E; Plotkin J; Jones DR; Sadelain M
Sci Transl Med; 2014 Nov; 6(261):261ra151. PubMed ID: 25378643
[TBL] [Abstract][Full Text] [Related]
8. Defect in recruiting effector memory CD8+ T-cells in malignant pleural effusions compared to normal pleural fluid.
Scherpereel A; Grigoriu BD; Noppen M; Gey T; Chahine B; Baldacci S; Trauet J; Copin MC; Dessaint JP; Porte H; Labalette M
BMC Cancer; 2013 Jul; 13():324. PubMed ID: 23816056
[TBL] [Abstract][Full Text] [Related]
9. Precision immunotherapy; dynamics in the cellular profile of pleural effusions in malignant mesothelioma patients.
Lievense LA; Bezemer K; Cornelissen R; Kaijen-Lambers ME; Hegmans JP; Aerts JG
Lung Cancer; 2017 May; 107():36-40. PubMed ID: 27168021
[TBL] [Abstract][Full Text] [Related]
10. Secretion of intelectin-1 from malignant pleural mesothelioma into pleural effusion.
Tsuji S; Tsuura Y; Morohoshi T; Shinohara T; Oshita F; Yamada K; Kameda Y; Ohtsu T; Nakamura Y; Miyagi Y
Br J Cancer; 2010 Aug; 103(4):517-23. PubMed ID: 20628387
[TBL] [Abstract][Full Text] [Related]
11. Multifactorial T-cell hypofunction that is reversible can limit the efficacy of chimeric antigen receptor-transduced human T cells in solid tumors.
Moon EK; Wang LC; Dolfi DV; Wilson CB; Ranganathan R; Sun J; Kapoor V; Scholler J; Puré E; Milone MC; June CH; Riley JL; Wherry EJ; Albelda SM
Clin Cancer Res; 2014 Aug; 20(16):4262-73. PubMed ID: 24919573
[TBL] [Abstract][Full Text] [Related]
12. Involvement of the M-CSF/IL-34/CSF-1R pathway in malignant pleural mesothelioma.
Blondy T; d'Almeida SM; Briolay T; Tabiasco J; Meiller C; Chéné AL; Cellerin L; Deshayes S; Delneste Y; Fonteneau JF; Boisgerault N; Bennouna J; Grégoire M; Jean D; Blanquart C
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32581053
[TBL] [Abstract][Full Text] [Related]
13. Immune biomarkers PD-1/PD-L1 and TLR3 in malignant pleural mesotheliomas.
Combaz-Lair C; Galateau-Sallé F; McLeer-Florin A; Le Stang N; David-Boudet L; Duruisseaux M; Ferretti GR; Brambilla E; Lebecque S; Lantuejoul S
Hum Pathol; 2016 Jun; 52():9-18. PubMed ID: 26980049
[TBL] [Abstract][Full Text] [Related]
14. CAR T-cell therapy for lung cancer and malignant pleural mesothelioma.
Zeltsman M; Dozier J; McGee E; Ngai D; Adusumilli PS
Transl Res; 2017 Sep; 187():1-10. PubMed ID: 28502785
[TBL] [Abstract][Full Text] [Related]
15. Targeting fibroblast activation protein in tumor stroma with chimeric antigen receptor T cells can inhibit tumor growth and augment host immunity without severe toxicity.
Wang LC; Lo A; Scholler J; Sun J; Majumdar RS; Kapoor V; Antzis M; Cotner CE; Johnson LA; Durham AC; Solomides CC; June CH; Puré E; Albelda SM
Cancer Immunol Res; 2014 Feb; 2(2):154-66. PubMed ID: 24778279
[TBL] [Abstract][Full Text] [Related]
16. Intrapleural immunotherapy: An update on emerging treatment strategies for pleural malignancy.
Murthy V; Katzman D; Sterman DH
Clin Respir J; 2019 May; 13(5):272-279. PubMed ID: 30810270
[TBL] [Abstract][Full Text] [Related]
17. New therapeutic strategies for malignant pleural mesothelioma.
Bonelli MA; Fumarola C; La Monica S; Alfieri R
Biochem Pharmacol; 2017 Jan; 123():8-18. PubMed ID: 27431778
[TBL] [Abstract][Full Text] [Related]
18. A Narrative Review-Management of Malignant Pleural Effusion Related to Malignant Pleural Mesothelioma.
Qureshi M; Thapa B; Muruganandan S
Heart Lung Circ; 2023 May; 32(5):587-595. PubMed ID: 36925448
[TBL] [Abstract][Full Text] [Related]
19. Pleural effusion VEGF levels as a prognostic factor of malignant pleural mesothelioma.
Hirayama N; Tabata C; Tabata R; Maeda R; Yasumitsu A; Yamada S; Kuribayashi K; Fukuoka K; Nakano T
Respir Med; 2011 Jan; 105(1):137-42. PubMed ID: 21041073
[TBL] [Abstract][Full Text] [Related]
20. What's the place of immunotherapy in malignant mesothelioma treatments?
Grégoire M
Cell Adh Migr; 2010; 4(1):153-61. PubMed ID: 20179421
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]